ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is ANI Pharmaceuticals, Inc. ?
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Net Sales has grown by an annual rate of 32.93%
3
With a growth in Operating Profit of 26.47%, the company declared Outstanding results in Sep 25
- OPERATING CASH FLOW(Y) Highest at USD 170.72 MM
- NET SALES(Q) Highest at USD 227.81 MM
- OPERATING PROFIT(Q) Highest at USD 45.46 MM
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 7.36% over the previous quarter.
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to ANI Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ANI Pharmaceuticals, Inc. for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
ANI Pharmaceuticals, Inc.
12.26%
0.35
36.69%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
32.93%
EBIT Growth (5y)
35.40%
EBIT to Interest (avg)
-0.55
Debt to EBITDA (avg)
36.46
Net Debt to Equity (avg)
1.18
Sales to Capital Employed (avg)
0.64
Tax Ratio
23.63%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.20%
ROE (avg)
1.25%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
73
Industry P/E
Price to Book Value
3.21
EV to EBIT
36.93
EV to EBITDA
13.62
EV to Capital Employed
2.31
EV to Sales
2.39
PEG Ratio
0.10
Dividend Yield
NA
ROCE (Latest)
6.25%
ROE (Latest)
4.38%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend40What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 170.72 MM
NET SALES(Q)
Highest at USD 227.81 MM
OPERATING PROFIT(Q)
Highest at USD 45.46 MM
PRE-TAX PROFIT(Q)
Highest at USD 16.96 MM
NET PROFIT(Q)
Highest at USD 10.87 MM
RAW MATERIAL COST(Y)
Fallen by -4.82% (YoY
CASH AND EQV(HY)
Highest at USD 495.06 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 2.8 times
DEBTORS TURNOVER RATIO(HY)
Highest at 3.68 times
OPERATING PROFIT MARGIN(Q)
Highest at 19.96 %
EPS(Q)
Highest at USD 1.13
-6What is not working for the Company
INTEREST(HY)
At USD 12.95 MM has Grown at 85.33%
Here's what is working for ANI Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 16.96 MM has Grown at 756.1%
over average net sales of the previous four periods of USD -2.58 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 10.87 MM has Grown at 830.08%
over average net sales of the previous four periods of USD -1.49 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 170.72 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 227.81 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD 45.46 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 16.96 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 10.87 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 227.81 MM has Grown at 21.92%
over average net sales of the previous four periods of USD 186.85 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at 19.96 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at USD 1.13
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 495.06 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 2.8 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.68 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -4.82% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for ANI Pharmaceuticals, Inc.
Interest
At USD 12.95 MM has Grown at 85.33%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
